GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AgomAb Therapeutics NV American Depositary Shares AGMB · USD

US listing · 🇺🇸 United States

Compare

7.55

-1.18%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About AgomAb Therapeutics NV American Depositary Shares

Its shares trade under the ticker AGMB. It has been listed since 6 February 2026.

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
6 Feb 2026
Website
agomab.com ↗
Head office
POSTHOFLEI 1/6, ANTWERPEN, 2600
Incorporated in
C9
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company develops novel disease-modifying therapies for immunology and inflammatory diseases.
  • Product pipeline includes Ontunisertib in Phase 2a trials for Crohn's disease.
  • Company was incorporated in 2017 and headquartered in Antwerp, Belgium.

Weaknesses

  • Sector and industry are listed as unknown in the provided data.
  • IPO date is scheduled for 2026-02-06, indicating future market entry.
  • Website is provided but no additional details about company operations are given.

Opportunities

  • Ontunisertib is in Phase 2a clinical trials for Fibrostenosing Crohn's disease.
  • AGMB-447 is in Phase 1 clinical trials for idiopathic pulmonary fibrosis.
  • AGMB-101 shows antifibrotic and regenerative activity in preclinical models.

Threats

  • Sector and industry are unknown, potentially hindering market analysis.
  • IPO is scheduled for 2026, which may delay revenue generation.
  • Company is incorporated in Belgium but headquartered in Antwerp, Belgium, which may cause operational confusion.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.